Lataa...
STING Agonist Combined to a Protein-Based Cancer Vaccine Potentiates Peripheral and Intra-Tumoral T Cell Immunity
Combining different immunotherapy approaches is currently building the future of immunotherapy, with the view to maximize anti-tumoral efficacy for larger patient population. The KISIMA™ platform allows the development of protein-based cancer vaccines able to induce tumor-specific T cell response re...
Tallennettuna:
| Julkaisussa: | Front Immunol |
|---|---|
| Päätekijät: | , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Frontiers Media S.A.
2021
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8283310/ https://ncbi.nlm.nih.gov/pubmed/34276686 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2021.695056 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|